Results 121 to 130 of about 270,350 (354)

The risk of death according to left ventricular ejection fraction and right ventricular dilatation in 17 321 adults with heart failure from 40 high‐, middle‐ and low‐income countries – A Global Congestive Heart Failure (G‐CHF) study

open access: yesEuropean Journal of Heart Failure, EarlyView.
Abstract Aims The aim of this study was to describe the prognostic importance of left ventricular ejection fraction (LVEF) versus right ventricular (RV) dilatation and dysfunction in patients with heart failure (HF) from countries of different income levels. Methods and results We enrolled 17 321 participants with HF from 40 countries.
Darryl P. Leong   +16 more
wiley   +1 more source

Cardiac rhythm devices in heart failure with reduced ejection fraction – role, timing, and optimal use in contemporary practice. European Journal of Heart Failure expert consensus document

open access: yesEuropean Journal of Heart Failure, EarlyView.
Abstract Guidelines for management of heart failure with reduced ejection fraction (HFrEF) emphasize personalized care, patient engagement, and shared decision‐making. Medications and cardiac rhythm management (CRM) devices are recommended with a high level of evidence. However, there are significant disparities: patients who could benefit from devices
Biykem Bozkurt   +15 more
wiley   +1 more source

The use of left ventricular ejection fraction in the diagnosis and management of heart failure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS)

open access: yesEuropean Journal of Heart Failure, EarlyView.
Abstract This clinical consensus statement revisits the role of left ventricular ejection fraction (LVEF) as a measurement of cardiac function, a prognostic marker and a major criterion to classify patients with heart failure, and gives new advice for clinical practice.
Giuseppe M.C. Rosano   +20 more
wiley   +1 more source

Pathological features of hypertrophic obstructive cardiomyopathy [PDF]

open access: bronze, 1974
Michael J. Davies   +2 more
openalex   +1 more source

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

open access: yesThe Lancet, 2020
I. Olivotto   +87 more
semanticscholar   +1 more source

Clinical and plasma proteomic characterization of heart failure with supranormal left ventricular ejection fraction: An emerging entity of heart failure

open access: yesEuropean Journal of Heart Failure, EarlyView.
Heart failure (HF) with supranormal ejection fraction (HFsnEF) is an unnoticed but emerging entity in HF. This study showed that HFsnEF carries a similarly increased cardiovascular risk as HF with reduced ejection fraction (HFrEF) and distinct structural and proteomic characteristics from HFrEF, warranting a further comprehensive understanding and ...
Yasuhiko Sakata   +19 more
wiley   +1 more source

Septal-free wall disproportion in inferior infarction: the echocardiographic differentiation from hypertrophic cardiomyopathy. [PDF]

open access: bronze, 1978
Alexandra Minna Stern   +4 more
openalex   +1 more source

Cancer therapy‐related cardiotoxicity is associated with distinct alterations of the myocardial lipidome

open access: yesEuropean Journal of Heart Failure, EarlyView.
Lipidome changes in anthracycline‐induced cardiotoxicity (AIC). Aims Anthracyclines are key components of various chemotherapy regimens, but their clinical utility is limited by severe cardiotoxic side effects. Previous studies have suggested that anthracycline‐induced cardiotoxicity (AIC) may be driven by alterations in myocardial lipid metabolism ...
Vera M. Braun   +6 more
wiley   +1 more source

Prediction and prognostic role of left ventricular systolic dysfunction in family screening for dilated cardiomyopathy and non‐dilated left ventricular cardiomyopathy

open access: yesEuropean Journal of Heart Failure, EarlyView.
Aims The prognostic significance of detecting left ventricular (LV) systolic dysfunction during family screening programmes (FSPs) in relatives of probands affected by dilated (DCM) and non‐dilated left ventricular (NDLVC) cardiomyopathies remain unclear.
Eva Del Mestre   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy